Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
ALMEIDA, Isabel Junqueira de
Citação
MOVEMENT DISORDERS CLINICAL PRACTICE, v.11, n.3, p.238-247, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundCorticobasal syndrome (CBS) is associated with diverse underlying pathologies, including the four-repeat (4R)-tauopathies. The Movement Disorders Society (MDS) criteria for progressive supranuclear palsy (PSP) proposed the novel category ""probable 4R-tauopathy"" to address the phenotypic overlap between PSP and corticobasal degeneration (CBD).ObjectivesTo investigate the clinical ability of the MDS-PSP criteria for probable 4R-tauopathy in predicting a negative amyloid-PET in CBS. Additionally, this study aims to explore CBS patients classified as 4R-tauopathy concerning their clinical features and neuroimaging degeneration patterns.MethodsThirty-two patients with probable CBS were prospectively evaluated and split into those who fulfilled or did not fulfill the 4R-tauopathy criteria (CBS-4RT+ vs. CBS-4RT-). All patients underwent positron emission tomographies (PET) with [18F]fluorodeoxyglucose and [11C]Pittsburgh Compound-B (PIB) on a hybrid PET-MRI scanner to perform multimodal quantitative comparisons with a control group.ResultsEleven patients were clinically classified as CBS-4RT+, and only one had a positive PIB-PET. The CBS-4RT+ classification had 92% specificity, 52% sensitivity, and 69% accuracy in predicting a negative PIB-PET. The CBS-4RT+ group presented with dysarthria and perseveration more often than the CBS-4RT- group. Moreover, the CBS-4RT+ group showed a prominent frontal hypometabolism extending to the supplementary motor area and striatum, and brain atrophy at the anterior cingulate and bilateral striata.ConclusionsThe 4R-tauopathy criteria were highly specific in predicting a negative amyloid-PET in CBS. Patients classified as 4R-tauopathy presented distinct clinical aspects, as well as brain metabolism and atrophy patterns previously associated with tauopathies.
Palavras-chave
tauopathies, corticobasal syndrome, progressive supranuclear palsy, positron emission tomography, amyloid PET
URI
https://observatorio.fm.usp.br/handle/OPI/58920
Referências
  1. Alexander SK, 2014, J NEUROL NEUROSUR PS, V85, P923, DOI 10.1136/jnnp-2013-307035
  2. Armstrong MJ, 2013, NEUROLOGY, V80, P496, DOI 10.1212/WNL.0b013e31827f0fd1
  3. Boeve BF, 2003, ANN NEUROL, V54, pS15, DOI 10.1002/ana.10570
  4. Boxer AL, 2019, LANCET NEUROL, V18, P549, DOI 10.1016/S1474-4422(19)30139-5
  5. Brendel M, 2020, JAMA NEUROL, V77, P1408, DOI 10.1001/jamaneurol.2020.2526
  6. Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014
  7. Burrell JR, 2014, MOVEMENT DISORD, V29, P684, DOI 10.1002/mds.25872
  8. Cassidy Adam, 2016, Pract Neurol, V16, P317, DOI 10.1136/practneurol-2015-001354
  9. Cerami C, 2020, J ALZHEIMERS DIS, V76, P517, DOI 10.3233/JAD-200153
  10. César KG, 2017, INT PSYCHOGERIATR, V29, P1345, DOI 10.1017/S1041610217000734
  11. Coutinho AM, 2020, EUR J NUCL MED MOL I, V47, P2666, DOI 10.1007/s00259-020-04714-0
  12. Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S
  13. Della Rosa PA, 2014, NEUROINFORMATICS, V12, P575, DOI 10.1007/s12021-014-9235-4
  14. Faria DD, 2019, BRAZ J PSYCHIAT, V41, P101, DOI 10.1590/1516-4446-2017-0002
  15. Goetz CG, 2004, MOVEMENT DISORD, V19, P1020, DOI 10.1002/mds.20213
  16. Grimm MJ, 2019, MOVEMENT DISORD, V34, P1228, DOI 10.1002/mds.27666
  17. Höglinger GU, 2021, LANCET NEUROL, V20, P182, DOI 10.1016/S1474-4422(20)30489-0
  18. Höglinger GU, 2018, MOV DISORD CLIN PRAC, V5, P141, DOI 10.1002/mdc3.12582
  19. Höglinger GU, 2017, MOVEMENT DISORD, V32, P853, DOI 10.1002/mds.26987
  20. Horie K, 2022, NAT MED, V28, P2547, DOI 10.1038/s41591-022-02075-9
  21. HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566
  22. Jabbari E, 2020, JAMA NEUROL, V77, P377, DOI 10.1001/jamaneurol.2019.4347
  23. Josephs KA, 2008, NEUROBIOL AGING, V29, P280, DOI 10.1016/j.neurobiolaging.2006.09.019
  24. Koga S, 2022, J NEUROL NEUROSUR PS, V93, P919, DOI 10.1136/jnnp-2021-328586
  25. Lee SE, 2011, ANN NEUROL, V70, P327, DOI 10.1002/ana.22424
  26. Ling HL, 2010, BRAIN, V133, P2045, DOI 10.1093/brain/awq123
  27. Litvan I, 2023, J NEUROL NEUROSUR PS, V94, P330, DOI 10.1136/jnnp-2022-330564
  28. Mathew R, 2012, J NEUROL NEUROSUR PS, V83, P405, DOI 10.1136/jnnp-2011-300875
  29. Mathew R, 2011, DEMENT GERIATR COGN, V31, P254, DOI 10.1159/000327169
  30. NITRINI R, 1987, Arquivos de Neuro-Psiquiatria, V45, P29
  31. Olfati N., 2022, FRONT NEUROL, V14
  32. Ouchi H, 2014, MOVEMENT DISORD, V29, P238, DOI 10.1002/mds.25746
  33. Palleis C, 2021, MOVEMENT DISORD, V36, P2104, DOI 10.1002/mds.28624
  34. Pardini M, 2019, NEUROLOGY, V92, pE1121, DOI 10.1212/WNL.0000000000007038
  35. Parmera JB, 2021, MOVEMENT DISORD, V36, P651, DOI 10.1002/mds.28373
  36. Parmera Jacy Bezerra, 2016, Dement. neuropsychol., V10, P267
  37. Parmera JB., 2021, FRONT NEUROL, V12, P1
  38. Peterson KA, 2021, J NEUROL, V268, P796, DOI 10.1007/s00415-019-09463-1
  39. PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323
  40. Respondek G, 2020, MOVEMENT DISORD, V35, P171, DOI 10.1002/mds.27872
  41. Rittman T, 2013, J NEUROL NEUROSUR PS, V84, P544, DOI 10.1136/jnnp-2012-303618
  42. Rivaud-Péchoux S, 2000, NEUROLOGY, V54, P1029, DOI 10.1212/WNL.54.5.1029
  43. Robinson JL, 2020, J NEUROPATH EXP NEUR, V79, P296, DOI 10.1093/jnen/nlz141
  44. Robinson JL, 2018, BRAIN, V141, P2181, DOI 10.1093/brain/awy146
  45. Santos-Santos MA, 2016, JAMA NEUROL, V73, P733, DOI 10.1001/jamaneurol.2016.0412
  46. Shelley BP, 2009, MOVEMENT DISORD, V24, P1593, DOI 10.1002/mds.22558
  47. Stamelou M, 2021, NAT REV NEUROL, V17, P601, DOI 10.1038/s41582-021-00541-5
  48. Whitwell JL, 2020, NEUROIMAGE-CLIN, V25, DOI 10.1016/j.nicl.2019.102152
  49. Yamane T, 2017, EUR J NUCL MED MOL I, V44, P850, DOI 10.1007/s00259-016-3591-2
  50. Yassuda Mônica Sanches, 2017, Dement. neuropsychol., V11, P48, DOI 10.1590/1980-57642016dn11-010008
  51. Zalewski N, 2014, J NEUROL, V261, P710, DOI 10.1007/s00415-014-7256-4

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE